scholarly journals Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Khalid Dafaallah Awadelkarim ◽  
Renato Mariani-Costantini ◽  
Ihsan Osman ◽  
Massimo Costanzo Barberis
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Interquartile Range ◽  
Labeling Index ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Significant Group ◽  
Cancer Subtypes ◽  
Her 2

Ki-67 labeling index has been linked to patient outcome in breast cancer patients. However, very few published reports have examined Ki-67 labeling index in African breast cancer patients. Sixty-two Sudanese breast cancer patients with primary invasive tumors were immunostained for Ki-67, ER, PR, Her-2/neu, CK5/6, and CK17. Ki-67 labeling index ranged from 0% to 50%, with a median of 5% (interquartile range 0–10). Low Ki-67 labeling index (immunostaining < 10%) was detected in 43/62 (69.4%) with a median of 0 (interquartile range 0–5), whereas high Ki-67 labeling index (immunostaining ≥ 10%) was revealed in 19/62 (30.6%) with a median of 20 (interquartile range 12–26). Ki-67 labeling index was significantly associated with tumor grade (P=0.022, Mann-Whitney U Test). There were no significant group differences between Ki-67 labeling index and ER (P=0.43), PR (P=0.7), Her-2/neu (P=0.45), CK5/6 (P=0.29), CK17 (P=0.55), pathologic stage (P=0.4), tumor histology (P=0.99), breast cancer subtypes (P=0.47), tumor size (P=0.16), and age at diagnosis (P=0.6). These results suggested that Ki-67 labeling index correlates with tumor differentiation and not with the tumor size or any other tested marker in Sudanese breast cancers. Thus, Ki-67 labeling index could be considered as a reliable measure of tumor proliferative fraction in Sudan.

scholarly journals Gambaran Usia dan Stadium Klinis Pasien Kanker Payudara yang dilakukan Pemeriksaan Imunohistokimia di Rumah Sakit Abdul Wahab Sjahranie pada Tahun 2018

2020 ◽  
Vol 8 (2) ◽  
pp. 126-140
Author(s):  
Ade Yusuf Yulianto ◽  
Hadi Irawiraman ◽  
P.M.T. Mangalindung Ompusunggu
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Clinical Stage ◽  
Descriptive Study ◽  
Regional Hospital ◽  
Breast Cancer Patients ◽  
Immunohistochemical Examination ◽  
Ki 67 ◽  
Her 2

ABSTRACKBreast cancer still occupies the highest incidence of all types of malignancies in women. Based on data recorded at Abdul Wahab Sjahrenie Hospital, 200 new cases are found each year. Immunohistochemical profile examination has been used extensively as a basis for classifying breast cancer molecularly. Expression of hormone receptors (ER, PR) and HER-2 found in immunohistochemical examinations are useful for determining therapeutic options that fit the patient's needs. The purpose of this descriptive study was to determine the characteristics of the immunohistochemical profile of breast cancer patients in Abdul Wahab Sjahranie Regional Hospital Samarinda in the January-December 2018 period based on age and clinical stage that had been examined by immunohistochemical examination including the expression of ER PR, Ki-67 and HER2. Method: This study used a cross-sectional descriptive study design by taking secondary data from breast cancer patients who had performed immunohistochemical examinations at Abdul Wahab Sjahranie Regional Hospital Samarinda in the January 2018 - December 2018 period. From 479 breast cancer patients came to Abdul Wahab Regional Hospital Sjahranie Samarinda, only 177 (37.18%) patients did immunohistochemical examinations. Most patients aged 40-49 were 65 patients (36.7%) had breast cancer, the highest clinical stage IIIB with 92 cases (52%), the Ki-67 with severe highest interpretation, range> 30% with 73 patients (41.2%), more positive ER than negative, in 93 patients (52.5%), while negative examination results 84 patients (47.5%). PR is the same as ER, which is 96 patients (54.2%), while negative examination results are 81 patients (45.8%). Most HER-2 results were negative, in 109 patients (61.6%). In this study the highest number of cases of breast cancer patients ranged between the ages of 40-49 years and at least aged 70 years and above. The clinical stage is most often found in stage IIIB (advanced). Ki-67 examination was found most frequently in severe interpretations. Examination of estrogen receptors is found to be most widely in positive interpretation. Positive progesterone tests to be most widely than negative examinations. Her-2 examination was found to be most widely in negative interpretation Keywords: Immunohistochemical examination, Hormone receptors, HER-2, Clinical Stadium

Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients

Breast Cancer ◽  
2012 ◽  
Vol 21 (3) ◽  
pp. 325-333 ◽  
Author(s):  
Kentaro Tamaki ◽  
Takanori Ishida ◽  
Nobumitsu Tamaki ◽  
Yoshihiko Kamada ◽  
Kanou Uehara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Labeling Index ◽  
Breast Cancer Patients ◽  
Ki 67

scholarly journals Correlation of Ki67 Expression with Hormone Receptors, Human Epidermal Growth Factor Receptor-2 (HER-2) Status, P53 Mutation and Clinicopathological Characteristics in Pathologic Specimens of Breast Cancer Patients

2016 ◽  
Vol 5 (2) ◽  
pp. 90-97
Author(s):  
Seyed Abbas Mirmalek ◽  
Maedeh Ghorbani ◽  
Ala Gholamrezaei Boushehrinejad ◽  
Masoud Salehi ◽  
Seyed Alireza Salimi-Tabatabaee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Lymph Node ◽  
Growth Factor ◽  
Tumor Size ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Her 2 ◽  
Epidermal Growth

Background: Breast cancer is the main cause of cancer in women and the second cause of ma­lignancy deaths. Ki-67 is one of the molecular markers used to evaluate cancer prognosis along with other factors such as age, tumor size, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), P53, human epidermal growth factor receptor-2 (HER-2), histolog­ical and nuclear grades. This study was aimed to evaluate the correlation of KI-67 expression with some biomarkers and clinico-pathological characteristics in breast cancer patients. Mate­rials and Methods: A total of 513 cases (all female) aged 40- 80 years, were randomly selected from patients who were admitted in two centers affiliated with Tehran University of Medical Sciences (Buo-alli and Kasra hospitals) over a 7-year period (2010-2015). Assessment of tumors for HER-2, P53, ER PR, pathological type and histologic grade was performed. Ki-67 labelling index (Ki-67LI) was defined as the percentage of MIB1-positive cells among a total number of 1,000 malignant cells at high-power magnification (×400). Results: Our study showed that age, ER and PR status were negatively correlated with Ki-67LI (P<0.05). Moreover, number of lymph nodes involved, HER-2, P53 and nuclear grades had a positive correlation with Ki-67LI (P<0.05), whereas, tumor size and histological grade showed no significant correlation with Ki-67LI (P =0.195 and P=0.721, respectively). Conclusion: Results of our study and other studies confirm that the expression of Ki-67 is significantly associated with ER, PR, HER-2 and P53 status. On the other hand, Ki-67 relationship with clinical characteristics such as age, tumor size and lymph node metastasis is not completely established and needs further research.[GMJ.2016;5(2):90-97]

Impact of selected tumor and patient characteristics on outcome of lymph node-positive breast cancer patients.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 66-66
Author(s):  
Ahmed Aly Nagy ◽  
Hager Ibrahim ◽  
Lamiaa Eid ◽  
Fatma Sayed ◽  
Mohamed Reda Kelany ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Tumor Size ◽  
Patient Characteristics ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Her 2 ◽  
Lymph Node Positive ◽  
Positive Breast Cancer

66 Background: Axillary lymph node (ALN) involvement remains the most significant factor affecting long term survival in breast cancer (BC) patients, and the risk of treatment failure is increased with the higher the number of ALN involvement, The aim of this study was to determine the impact of tumor characteristics; tumor size and number of positive lymph nodes and, ER and HER-2, as well as patient characteristics on DFS of patients with Lymph node positive Breast Cancer Patients who received Adjuvant Treatment. Methods: We retrospectively reviewed data of 704 patients with BC and ALN involvement who received adjuvant treatment in the period between 2010 and 2012. DFS outcomes were estimated with the Kaplan-Meier method and compared using the log rank test to determine. The effect of prognostic factors on BC outcomes. Results: Median age was 50 years (SD±12.024, Range 21-88). About 83.7% of the tumors were IDC,. About 30.4%of the tumors were grade III. Median tumor size was 5 cm (SD± 1.3745, Range 1-7).Median number of positive axillary LN was 4 (SD± 4.987, Range 1-37). Regarding receptor expression; 21.2% were HER-2 +ve, 58.7% were ER +ve and about 30.4 were triple negative. Median DFS was 20 months (SD± 14.511, Range 1-60). Cox regression showed that age, positive ER status and more than 3 ALN involvement had a statistically significant impact on DFS ( p<0.001 for all ), however, Tumor size, HER-2 overexpression, patient menstrual status had no significant effect. ER positive age >50 years was associated with prolonged DFS of 23 months (95%CI=20.641-25.359) versus 19 months (95% CI=17.598-20.402) for age≤50 years (p<0.001). ER positive status was associated with prolonged DFS of 22 months (95%CI=20.290-23.710) versus 17 months (95% CI=14.049-19.951) for ER negative (p<0.001).The group of patients with ≤3 positive dissected LN was associated with statistically significant prolonged DFS of 25 months (95%CI=22.286-27.714) versus 15 months (95%CI = 12.353-17.647) for patients with>3 positive dissected LN (p<0.001). Conclusions: These study indicate that the age, ER status and more than 3 ALN involvement have impact on DFS in Lymph node positive Breast Cancer Patients.

Prognostic significance of HER-2/neu over-expression on the incidence of brain metastasis in newly diagnosed breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 649-649 ◽  
Author(s):  
B. S. Abdulkarim ◽  
Z. Gabos ◽  
R. Sinha ◽  
J. Hanson ◽  
N. Chauhan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Size ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Over Expression ◽  
Increased Risk ◽  
Her 2

649 Background: As systemic therapy improves, brain metastases (BM) from breast cancer are becoming increasingly evident. An increased risk of BM in HER-2/neu over-expressing metastatic breast cancer patients has been suggested. However, the relationship between HER-2/neu over-expression and the risk of BM in newly diagnosed breast cancer patients is unknown. Methods: To determine incidence of BM in HER-2/neu over-expressing breast cancer patients, a cohort of patients between 01/1998 and 12/2003 with uniform HER-2/neu testing were identified from a cancer registry. A total of 460 patients with HER-2/neu over-expression and 500 patients with HER-2/neu negative disease were reviewed. Patients were excluded if there was breast cancer diagnosed before 01/1998 or others cancer. A total of 301 HER-2/neu over-expressing and 363 HER-2/neu negative patients were included for this analysis. The association between histological features and the occurrence of BM were evaluated with univariate and multivariate analyses. Results: BM were identified in 8% (24 patients) of HER-2/neu over-expressing breast cancer patients compared to only 1.7% (6 patients) in the HER-2/neu negative patients (hazard ratio 5.15 [2.079–12.78], p=0.0001). In patients with recurrent disease, the proportion of BM for HER-2/neu over-expressing patients was 24% compared to 10% in HER-2/neu negative patients. HER-2/neu over-expression, tumor size >2cm, ≥ 4 nodes positive and grade 2/3 were predictors of BM in univariate analysis. In multivariate analysis, HER-2/neu over-expression and tumor size>2cm were an independent prognostic factors for the development of BM, while hormone receptors expressions was protective (p=0.02). Conclusions: Our population based study show that newly diagnosed HER-2/neu over-expressing breast cancer patients are at significantly increased risk for BM. As most BM occur in HER-2/neu over-expressing patients with systemic metastatic disease, these findings could prompt consideration of brain prophylaxis strategies and/or serial radiologic screening to detect asymptomatic BM. No significant financial relationships to disclose.

Explanation model using pathological data for treatment outcome of patients with early-stage breast cancer with hormonal receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12006-e12006
Author(s):  
Naiyarat Prasongsook
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Hormonal Therapy ◽  
Tumor Size ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Ki 67

e12006 Background: The decision to initiate adjuvant chemotherapy for early-stage breast cancer patients with HR+ and HER2- is still unclear. Although the 21-gene Recurrence Score (RS) assay is a validated testing and becomes an emerging decision-making tool; it is still controversial guidance on adding adjuvant chemotherapy for patients with intermediate RS. This study aimed to develop the explanation model by using pathological information for prediction of the best outcome from adjuvant systemic treatment in these patients.Methods: Early-stage breast cancer patients with HR+, and HER2- who underwent complete resection registered within electronic medical record from 2003 to 2013 were included. Patient’s characteristics and pathological information were collected and analyzed. Univariate and multivariate analysis were conducted by using stepwise logistic regression. The explanation model was explored by using association between multivariate models and overall survival (OS).Results: 236 patients who underwent complete surgery treatment were included. 121 patients (51%) were treated with sequential adjuvant treatment, and 115 patients (48%) with anti-hormonal therapy alone. Clinicopathological parameters between two groups were demonstrated in Table1. Tumor size (≥2 – 5 cm), Estrogen receptor-negative/ Progesterone receptor-positive (ER-/PgR+), and Ki-67 expression were statistically significant multivariate independent prognostic factors for OS. When we adjusted for tumor size, HR status, and Ki-67 expression, the explanation model predicted 10-year OS was 99.2% for patients with sequential adjuvant treatment, whereas 89.5% for patients with adjuvant anti-hormonal alone (difference: 9.7%); p-value = 0.01.Conclusions: We found substantial discordance in 10-year OS benefit between early-breast cancer patients with HR+, HER2- with sequential adjuvant therapy and adjuvant hormonal therapy alone. Adjuvant chemotherapy should be considered in early-breast cancer patients with 2-3 cm in tumor size, ER-/PgR+, and Ki 67 expression.

Sign in / Sign up

Export Citation Format

Share Document